View in EDS HTML Full Text PDF Full Text

Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: A systematic review and meta-analysis.

Saved in:
Bibliographic Details
Title: Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: A systematic review and meta-analysis.
Authors: Hassan, Malak A. (AUTHOR), Awad, Abdelaziz A. (AUTHOR), Marey, Ahmed (AUTHOR), Amin, Ahmed Mostafa (AUTHOR), Elshahat, Ahmed (AUTHOR), El-Moslemani, Mohamed (AUTHOR), Mansour, Ahmed (AUTHOR), Ramadan, Shrouk (AUTHOR), Aldemerdash, Mohamed A. (AUTHOR)
Source: Neurological Sciences. Aug2025, Vol. 46 Issue 8, p3525-3536. 12p.
Subjects: Partial epilepsy, Child patients, People with epilepsy, Synaptic vesicles, Pediatric therapy
Abstract: Background: Brivaracetam is a novel third-generation antiseizure medication and an analog of levetiracetam with selective affinity for synaptic vesicle protein 2A (SV2A). By binding SV2A, brivaracetam decreases pre-synaptic neurotransmitter release. Aim: We aimed to assess the safety and efficacy of brivaracetam in pediatric epilepsy. Method: We searched PubMed, Scopus, and Web of Science (WOS) for relevant clinical and observational studies from inception until February 2024. We carried out statistical analysis using Open Meta-Analyst. Dichotomous data were pooled as proportions with a 95% confidence interval (CI). Results: Eleven studies with a total of 805 patients were identified. The analysis of four studies revealed the more than 50% responder rate in a cohort of 252 focal epilepsy patients to be 51.5% (95% CI: [32.6%, 70.5%]). The analysis of three studies involving a cohort of 266 patients found a 20.7% incidence (95% CI: [15.8%, 25.6%]) of complete seizure freedom. The analysis of nine studies involving a cohort of 737 epilepsy patients revealed a retention rate of 66% (95% CI: [40%, 92%]). Conclusion: This study highlights the efficacy, tolerability, and safety of brivaracetam as adjunctive therapy in pediatric patients with epilepsy. The findings support its consideration as a valuable treatment option for children and adolescents, particularly those with drug-resistant epilepsy. Further trials with longer follow-up durations are needed to study the optimal doses and explore factors affecting drug response. [ABSTRACT FROM AUTHOR]
Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 186678251
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: A systematic review and meta-analysis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Hassan%2C+Malak+A%2E%22">Hassan, Malak A.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Awad%2C+Abdelaziz+A%2E%22">Awad, Abdelaziz A.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Marey%2C+Ahmed%22">Marey, Ahmed</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Amin%2C+Ahmed+Mostafa%22">Amin, Ahmed Mostafa</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Elshahat%2C+Ahmed%22">Elshahat, Ahmed</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22El-Moslemani%2C+Mohamed%22">El-Moslemani, Mohamed</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mansour%2C+Ahmed%22">Mansour, Ahmed</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ramadan%2C+Shrouk%22">Ramadan, Shrouk</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Aldemerdash%2C+Mohamed+A%2E%22">Aldemerdash, Mohamed A.</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Neurological+Sciences%22">Neurological Sciences</searchLink>. Aug2025, Vol. 46 Issue 8, p3525-3536. 12p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Partial+epilepsy%22">Partial epilepsy</searchLink><br /><searchLink fieldCode="DE" term="%22Child+patients%22">Child patients</searchLink><br /><searchLink fieldCode="DE" term="%22People+with+epilepsy%22">People with epilepsy</searchLink><br /><searchLink fieldCode="DE" term="%22Synaptic+vesicles%22">Synaptic vesicles</searchLink><br /><searchLink fieldCode="DE" term="%22Pediatric+therapy%22">Pediatric therapy</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: Brivaracetam is a novel third-generation antiseizure medication and an analog of levetiracetam with selective affinity for synaptic vesicle protein 2A (SV2A). By binding SV2A, brivaracetam decreases pre-synaptic neurotransmitter release. Aim: We aimed to assess the safety and efficacy of brivaracetam in pediatric epilepsy. Method: We searched PubMed, Scopus, and Web of Science (WOS) for relevant clinical and observational studies from inception until February 2024. We carried out statistical analysis using Open Meta-Analyst. Dichotomous data were pooled as proportions with a 95% confidence interval (CI). Results: Eleven studies with a total of 805 patients were identified. The analysis of four studies revealed the more than 50% responder rate in a cohort of 252 focal epilepsy patients to be 51.5% (95% CI: [32.6%, 70.5%]). The analysis of three studies involving a cohort of 266 patients found a 20.7% incidence (95% CI: [15.8%, 25.6%]) of complete seizure freedom. The analysis of nine studies involving a cohort of 737 epilepsy patients revealed a retention rate of 66% (95% CI: [40%, 92%]). Conclusion: This study highlights the efficacy, tolerability, and safety of brivaracetam as adjunctive therapy in pediatric patients with epilepsy. The findings support its consideration as a valuable treatment option for children and adolescents, particularly those with drug-resistant epilepsy. Further trials with longer follow-up durations are needed to study the optimal doses and explore factors affecting drug response. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Neurological Sciences is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=186678251
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10072-025-08185-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 3525
    Subjects:
      – SubjectFull: Partial epilepsy
        Type: general
      – SubjectFull: Child patients
        Type: general
      – SubjectFull: People with epilepsy
        Type: general
      – SubjectFull: Synaptic vesicles
        Type: general
      – SubjectFull: Pediatric therapy
        Type: general
    Titles:
      – TitleFull: Efficacy and safety of Brivaracetam as adjunctive therapy in pediatric epilepsy: A systematic review and meta-analysis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hassan, Malak A.
      – PersonEntity:
          Name:
            NameFull: Awad, Abdelaziz A.
      – PersonEntity:
          Name:
            NameFull: Marey, Ahmed
      – PersonEntity:
          Name:
            NameFull: Amin, Ahmed Mostafa
      – PersonEntity:
          Name:
            NameFull: Elshahat, Ahmed
      – PersonEntity:
          Name:
            NameFull: El-Moslemani, Mohamed
      – PersonEntity:
          Name:
            NameFull: Mansour, Ahmed
      – PersonEntity:
          Name:
            NameFull: Ramadan, Shrouk
      – PersonEntity:
          Name:
            NameFull: Aldemerdash, Mohamed A.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: Aug2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 15901874
          Numbering:
            – Type: volume
              Value: 46
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: Neurological Sciences
              Type: main
ResultId 1